Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W)

Dougados, M; Wei, JCC; Landewe, R; Sieper, J; Baraliakos, X; Van den Bosch, F; Maksymowych, WP; Ermann, J; Walsh, JA; Tomita, T; Deodhar, A; van der Heijde, D; Li, XQ; Zhao, FY; Bertram, CC; Gallo, G; Carlier, H; Gensler, LS

Dougados, M (corresponding author), Univ Paris 05, Hop Cochin, Rheumatol, F-75014 Paris, France.

ANNALS OF THE RHEUMATIC DISEASES, 2020; 79 (2): 176

Abstract

Objectives To investigate the efficacy and safety of ixekizumab for up to 52 weeks in two phase 3 studies of patients with active radiographic axial s......

Download PDF


Full Text Link


打开APP